Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Context
2.2. Study Population and Sampling
2.3. Survey Development
2.4. Study Domains and Variables
2.5. Data Analysis
3. Results
3.1. COVID-19 Vaccine Willingness
3.2. Perceived COVID-19 Vaccine Safety among Specific Communities
3.3. Vaccination and the Health of Others
3.4. Exploring Potential Ambivalence
3.5. Information Sources
3.6. COVID-19 Vaccine Access
4. Discussion
Limitations
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Grasselli, G.; Zangrillo, A.; Zanella, A.; Antonelli, M.; Cabrini, L.; Castelli, A.; Cereda, D.; Coluccello, A.; Foti, G.; Fumagalli, R. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy. JAMA 2020, 323, 1574–1581. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Centers for Disease Control and Prevention. Geographic Differences in COVID-19 Cases, Deaths, and Incidence—United States, February 12–April 7, 2020. MMWR Morb. Mortal. Wkly. Rep. 2020, 69, 465–471. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ali, S.A.; Baloch, M.; Ahmed, N.; Ali, A.A.; Iqbal, A. The outbreak of Coronavirus Disease 2019 (COVID-19)—An emerging global health threat. J. Infect. Public Health 2020, 13, 644–646. [Google Scholar] [CrossRef]
- New York City Department of Health and Mental Hygiene. COVID-19 Data Interact and Visualize Dashboard. Available online: https://www.nyc.gov/site/doh/data/tools.page (accessed on 1 July 2022).
- Centers for Disease Control and Prevention. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies—United States, September 2021–February 2022. MMWR Morb. Mortal. Wkly. Rep. 2022, 71, 606–608. [Google Scholar] [CrossRef] [PubMed]
- Yehia, B.R.; Winegar, A.; Fogel, R.; Fakih, M.; Ottenbacher, A.; Jesser, C.; Bufalino, A.; Huang, R.-H.; Cacchione, J. Association of Race with Mortality Among Patients Hospitalized with Coronavirus Disease 2019 (COVID-19) at 92 US Hospitals. JAMA Netw. Open 2020, 3, e2018039. [Google Scholar] [CrossRef]
- Grebely, J.; Cerdá, M.; Rhodes, T. COVID-19 and the health of people who use drugs: What is and what could be? Intern J. Drug Policy 2020, 83, 102958. [Google Scholar] [CrossRef]
- Bennett, A.S.; Townsend, T.; Elliott, L. The COVID-19 pandemic and the health of people who use illicit opioids in New York City, the first 12 months. Int. J. Drug Policy 2021, 101, 103554. [Google Scholar] [CrossRef]
- Iversen, J.; Peacock, A.; Price, O.; Byrne, J.; Dunlop, A.; Maher, L. COVID-19 vaccination among people who inject drugs: Leaving no one behind. Drug Alcohol Rev. 2021, 40, 517–520. [Google Scholar] [CrossRef]
- Wang, Q.Q.; Kaelber, D.C.; Xu, R.; Volkow, N.D. COVID-19 risk and outcomes in patients with substance use disorders: Analyses from electronic health records in the United States. Mol. Psychiatry 2020, 26, 30–39. [Google Scholar] [CrossRef]
- Zhang, Y.; Khullar, D.; Wang, F.; Steel, P.; Wu, Y.; Orlander, D.; Weiner, M.; Kaushal, R. Socioeconomic variation in characteristics, outcomes, and healthcare utilization of COVID-19 patients in New York City. PLoS ONE 2021, 16, e0255171. [Google Scholar] [CrossRef]
- Lieberman-Cribbin, W.; Alpert, N.; Flores, R.; Taioli, E. A risk index for COVID-19 severity is associated with COVID-19 mortality in New York City. BMC Public Health 2021, 21, 1452. [Google Scholar] [CrossRef]
- Do, D.P.; Frank, R. Unequal burdens: Assessing the determinants of elevated COVID-19 case and death rates in New York City’s racial/ethnic minority neighbourhoods. J. Epidemiol. Community Health 2020, 75, 321–326. [Google Scholar] [CrossRef]
- Kim, B.; Rundle, A.G.; Goodwin, A.T.; Morrison, C.N.; Branas, C.C.; El-Sadr, W.; Duncan, D.T. COVID-19 testing, case, and death rates and spatial socio-demographics in New York City: An ecological analysis as of June 2020. Health Place 2021, 68, 102539. [Google Scholar] [CrossRef]
- Akbar, P.A.; Hickly, S.L.; Shertzer, A.; Walsh, R.P. Racial Segregation in Housing Markets and the Erosion of Black Wealth. Rev. Econ. Stat. 2022, 1–45. [Google Scholar] [CrossRef]
- Williams, D.R. Racial Residential Segregation: A Fundamental Cause of Racial Disparities in Health. Public Health Rep. 2001, 116, 404–416. [Google Scholar] [CrossRef]
- Woolhandler, S.; Himmelstein, D.U.; Ahmed, S.; Bailey, Z.; Bassett, M.T.; Bird, M.; Bor, J.; Bor, D.; Carrasquillo, O.; Chowkwanyun, M.; et al. Public policy and health in the Trump era. Lancet 2021, 397, 705–753. [Google Scholar] [CrossRef]
- Maani, N.; Van Schalkwyk, M.C.; Petticrew, M.; Galea, S. The Commercial Determinants of Three Contemporary National Crises: How Corporate Practices Intersect With the COVID-19 Pandemic, Economic Downturn, and Racial Inequity. Milbank Q. 2021, 99, 503. [Google Scholar] [CrossRef]
- Storm, S. Lessons for the Age of Consequences: COVID-19 and the Macroeconomy. Rev. Politi- Econ. 2021, 1–40. [Google Scholar] [CrossRef]
- Elekwachi, O.; Wingate, L.T.; Tasker, V.C.; Aboagye, L.; Dubale, T.; Betru, D.; Algatan, R. A Review of Racial and Ethnic Disparities in Immunizations for Elderly Adults. J. Prim. Care Community Health 2021, 12. [Google Scholar] [CrossRef]
- Egede, L.E.; Walker, R.J. Structural racism, social risk factors, and COVID-19—a dangerous convergence for Black Americans. N. Engl. J. Med. 2020, 383, e77. [Google Scholar] [CrossRef]
- Rondini, A.C.; Kowalsky, R.H. “First do no harm”: Clinical practice guidelines, mesolevel structural racism, and medicine’s epistemological reckoning. Soc. Sci. Med. 2021, 279, 113968. [Google Scholar] [CrossRef] [PubMed]
- Yearby, R.; Mohapatra, S. Law, structural racism, and the COVID-19 pandemic. J. Law Biosci. 2020, 7, lsaa036. [Google Scholar] [CrossRef] [PubMed]
- Krieger, N. Ecosocial Theory, Embodied Truths, and the People’s Health; Oxford University Press: Oxford, UK, 2021. [Google Scholar]
- Navarro, V. What is Happening in the United States? How Social Classes Influence the Political Life of the Country and its Health and Quality of Life. Int. J. Health Serv. 2021, 51, 125–134. [Google Scholar] [CrossRef]
- Jessell, L.; Zaidi, I.; Dominguez-Gomez, L.; Harocopos, A. Collecting Data During the COVID-19 Pandemic: Lessons from an In-Person Survey of People Who Use Opioids. Public Health Rep. 2022, 137, 272–277. [Google Scholar] [CrossRef]
- Dominguez Gomez, L.J.L.; Zaidi, I.; Nolan, M.; Harocopos, A. Basic Needs among People Who Use Opioids in New York City during the COVID-19 Pandemic; New York City Department of Health and Mental Hygiene: New York, NY, USA, 2020. [Google Scholar]
- Perlman, D.C.; Jordan, A.E. The Syndemic of Opioid Misuse, Overdose, HCV, and HIV: Structural-Level Causes and Interventions. Curr. HIV AIDS Rep. 2018, 15, 96–112. [Google Scholar] [CrossRef] [PubMed]
- Wang, L.; Wang, Q.; Davis, P.B.; Volkow, N.D.; Xu, R. Increased risk for COVID -19 breakthrough infection in fully vaccinated patients with substance use disorders in the United States between December 2020 and August 2021. World Psychiatry 2021, 21, 124–132. [Google Scholar] [CrossRef]
- Board, A.R.; Kim, S.; Park, J.; Schieber, L.; Miller, G.F.; Pike, J.; Cremer, L.; Asher, A. Risk Factors for COVID-19 among Persons with Substance Use Disorder (PWSUD) with Hospital Visits–United States, April 2020–December 2020. Drug Alcohol Depend 2022, 232, 109297. [Google Scholar] [CrossRef]
- Allen, B.; Shahawy, O.E.; Rogers, E.S.; Hochman, S.; Khan, M.R.; Krawczyk, N. Association of substance use disorders and drug overdose with adverse COVID-19 outcomes in New York City: January–October 2020. J. Public Health 2020, 43, 462–465. [Google Scholar] [CrossRef]
- Friedman, S.R.; Mateu-Gelabert, P.; Nikolopoulos, G.K.; Cerdá, M.; Rossi, D.; Jordan, A.E.; Townsend, T.; Khan, M.R.; Perlman, D.C. Big Events theory and measures may help explain emerging long-term effects of current crises. Glob. Public Health 2021, 16, 1167–1186. [Google Scholar] [CrossRef]
- Barocas, J.A. Business Not as Usual—COVID-19 Vaccination in Persons with Substance Use Disorders. N. Engl. J. Med. 2021, 384, e6. [Google Scholar] [CrossRef]
- Vilches, T.N.; Moghadas, S.M.; Sah, P.; Fitzpatrick, M.C.; Shoukat, A.; Pandey, A.; Galvani, A.P. Estimating COVID-19 Infections, Hospitalizations, and Deaths Following the US Vaccination Campaigns During the Pandemic. JAMA Netw. Open 2022, 5, e2142725. [Google Scholar] [CrossRef]
- Ehreth, J. The value of vaccination: A global perspective. Vaccine 2003, 21, 4105–4117. [Google Scholar] [CrossRef]
- Hinman, A. Eradication of vaccine-preventable diseases. Annu. Rev. Public Health 1999, 20, 211–229. [Google Scholar] [CrossRef]
- Pananos, A.D.; Bury, T.M.; Wang, C.; Schonfeld, J.; Mohanty, S.P.; Nyhan, B.; Salathé, M.; Bauch, C.T. Critical dynamics in population vaccinating behavior. Proc. Natl. Acad. Sci. USA 2017, 114, 13762–13767. [Google Scholar] [CrossRef] [Green Version]
- Phadke, V.K.; Bednarczyk, R.A.; Salmon, D.A.; Omer, S.B. Association between vaccine refusal and vaccine-preventable diseases in the United States: A review of measles and pertussis. JAMA 2016, 315, 1149–1158. [Google Scholar] [CrossRef] [Green Version]
- Rane, M.S.; Kochhar, S.; Poehlein, E.; You, W.; Robertson, M.M.; Zimba, R.; A Westmoreland, D.; Romo, M.L.; Kulkarni, S.G.; Chang, M.; et al. Determinants and Trends of COVID-19 Vaccine Hesitancy and Vaccine Uptake in a National Cohort of US Adults: A Longitudinal Study. Am. J. Epidemiol. 2022, 191, 570–583. [Google Scholar] [CrossRef]
- Wang, Q.; Yang, L.; Jin, H.; Lin, L. Vaccination against COVID-19: A systematic review and meta-analysis of acceptability and its predictors. Prev. Med. 2021, 150, 106694. [Google Scholar] [CrossRef]
- Jaiswal, J.; Halkitis, P.N. Towards a More Inclusive and Dynamic Understanding of Medical Mistrust Informed by Science. Behav. Med. 2019, 45, 79–85. [Google Scholar] [CrossRef]
- Kolar, S.K.; Wheldon, C.; Hernandez, N.D.; Young, L.; Romero-Daza, N.; Daley, E.M. Human Papillomavirus Vaccine Knowledge and Attitudes, Preventative Health Behaviors, and Medical Mistrust Among a Racially and Ethnically Diverse Sample of College Women. J. Racial Ethn. Health Disparities 2014, 2, 77–85. [Google Scholar] [CrossRef]
- Bajaj, S.S.; Stanford, F.C. Beyond Tuskegee—Vaccine distrust and everyday racism. New Engl. J. Med. 2021, 384, e12. [Google Scholar] [CrossRef]
- Muncan, B.; Walters, S.M.; Ezell, J.; Ompad, D.C. “They look at us like junkies”: Influences of drug use stigma on the healthcare engagement of people who inject drugs in New York City. Harm Reduct. J. 2020, 17, 1–9. [Google Scholar] [CrossRef] [PubMed]
- e Cruz, C.C.; Salom, C.L.; Dietze, P.; Lenton, S.; Burns, L.; Alati, R. Frequent experience of discrimination among people who inject drugs: Links with health and wellbeing. Drug Alcohol Depend. 2018, 190, 188–194. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Von Hippel, C.; Brener, L.; Horwitz, R. Implicit and explicit internalized stigma: Relationship with risky behaviors, psychosocial functioning and healthcare access among people who inject drugs. Addict. Behav. 2018, 76, 305–311. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Jaiswal, J.; LoSchiavo, C.; Perlman, D.C. Disinformation, Misinformation and Inequality-Driven Mistrust in the Time of COVID-19: Lessons Unlearned from AIDS Denialism. AIDS Behav. 2020, 24, 2776–2780. [Google Scholar] [CrossRef] [PubMed]
- Strathdee, S.A.; Abramovitz, D.; Harvey-Vera, A.Y.; Vera, C.; Rangel, G.; Artamonova, I.; Patterson, T.L.; Mitchell, R.; Bazzi, A.R. Correlates of COVID-19 Vaccine Hesitancy among People who Inject Drugs in the San Diego-Tijuana Border Region. Clin. Infect. Dis. 2022, 75, e726–e733. [Google Scholar] [CrossRef] [PubMed]
- Shmueli, L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health 2021, 21, 804. [Google Scholar] [CrossRef]
- Agley, J.; Xiao, Y. Misinformation about COVID-19: Evidence for differential latent profiles and a strong association with trust in science. BMC Public Health 2021, 21, 89. [Google Scholar] [CrossRef]
- Savoia, E.; Piltch-Loeb, R.; Goldberg, B.; Miller-Idriss, C.; Hughes, B.; Montrond, A.; Kayyem, J.; Testa, M. Predictors of COVID-19 Vaccine Hesitancy: Socio-Demographics, Co-Morbidity, and Past Experience of Racial Discrimination. Vaccines 2021, 9, 767. [Google Scholar] [CrossRef]
- Jaiswal, J.; LoSchiavo, C.; Maiolatesi, A.; Kapadia, F.; Halkitis, P.N. Misinformation, gendered perceptions, and low healthcare provider communication around HPV and the HPV vaccine among young sexual minority men in New York City: The p18 cohort study. J. Community Health 2020, 45, 702–711. [Google Scholar] [CrossRef]
- Shao, C.; Ciampaglia, G.L.; Varol, O.; Yang, K.-C.; Flammini, A.; Menczer, F. The spread of low-credibility content by social bots. Nat. Commun. 2018, 9, 4787. [Google Scholar] [CrossRef]
- Howard, P.N.; Woolley, S.; Calo, R. Algorithms, bots, and political communication in the US 2016 election: The challenge of automated political communication for election law and administration. J. Inf. Technol. Politi- 2018, 15, 81–93. [Google Scholar] [CrossRef] [Green Version]
- Joshi, A.; Kaur, M.; Kaur, R.; Grover, A.; Nash, D.; El-Mohandes, A. Predictors of COVID-19 Vaccine Acceptance, Intention, and Hesitancy: A Scoping Review. Front. Public Health 2021, 9, 698111. [Google Scholar] [CrossRef]
- Mondal, P.; Sinharoy, A.; Su, L. Sociodemographic predictors of COVID-19 vaccine acceptance: A nationwide US-based survey study. Public Health 2021, 198, 252–259. [Google Scholar] [CrossRef]
- Centers for Disease Control and Prevention. Patterns in COVID-19 vaccination coverage, by social vulnerability and ur-banicity—United States, December 14, 2020–May 1, 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 818. [Google Scholar] [CrossRef]
- Menza, T.W.; Capizzi, J.; Zlot, A.I.; Barber, M.; Bush, L. COVID-19 Vaccine Uptake Among People Living with HIV. AIDS Behav. 2022, 26, 2224–2228. [Google Scholar] [CrossRef]
- Jarlais, D.C.D.; Feelemyer, J.; LaKosky, P.; Szymanowski, K.; Arasteh, K. Expansion of Syringe Service Programs in the United States, 2015–2018. Am. J. Public Health 2020, 110, 517–519. [Google Scholar] [CrossRef]
- Altice, F.L.; Bruce, R.D.; Walton, M.R.; Buitrago, M.I. Adherence to Hepatitis B Virus Vaccination at Syringe Exchange Sites. J. Urban Health 2005, 82, 151–161. [Google Scholar] [CrossRef] [Green Version]
- Masson, C.L.; Delucchi, K.L.; McKnight, C.; Hettema, J.; Khalili, M.; Min, A.; Jordan, A.E.; Pepper, N.; Hall, J.; Hengl, N.S.; et al. A Randomized Trial of a Hepatitis Care Coordination Model in Methadone Maintenance Treatment. Am. J. Public Health 2013, 103, e81–e88. [Google Scholar] [CrossRef]
- Behrends, C.N.; Lu, X.; Corry, G.J.; LaKosky, P.; Prohaska, S.M.; Glick, S.N.; Kapadia, S.N.; Perlman, D.C.; Schackman, B.R.; Jarlais, D.C.D. Harm reduction and health services provided by syringe services programs in 2019 and subsequent impact of COVID-19 on services in 2020. Drug Alcohol Depend. 2022, 232, 109323. [Google Scholar] [CrossRef]
- Yeager, S.; Abramovitz, D.; Harvey-Vera, A.Y.; Vera, C.F.; Algarin, A.B.; Smith, L.R.; Rangel, G.; Artamonova, I.; Patterson, T.L.; Bazzi, A.R.; et al. A cross-sectional study of factors associated with COVID-19 testing among people who inject drugs: Missed opportunities for reaching those most at risk. BMC Public Health 2022, 22, 842. [Google Scholar] [CrossRef]
- World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19. 11 March 2020. Available online: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020 (accessed on 19 October 2022).
- Centers for Disease Control and Prevention. COVID-19 Outbreak—New York City, February 29–June 1, 2020. Morb. Mortal. Wkly. Rep. 2020, 69, 1725. [Google Scholar] [CrossRef] [PubMed]
- Centers for Disease Control and Prevention. Comparative effectiveness of Moderna, Pfizer-BioNTech, and Janssen (Johnson & Johnson) vaccines in preventing COVID-19 hospitalizations among adults without immunocompromising conditions—United States, March–August 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 1337. [Google Scholar]
- Williams, N.; Tutrow, H.; Pina, P.; Belli, H.M.; Ogedegbe, G.; Schoenthaler, A. Assessment of Racial and Ethnic Disparities in Access to COVID-19 Vaccination Sites in Brooklyn, New York. JAMA Netw. Open 2021, 4, e2113937. [Google Scholar] [CrossRef] [PubMed]
- Goodnough, A.; Hoffman, J. The wealthy are getting more vaccinations, even in poorer neighborhoods. The New York Times. 2021. Available online: https://www.nytimes.com/2021/02/02/health/white-people-covid-vaccines-minorities.html (accessed on 19 October 2022).
- Chou, W.-Y.S.; Budenz, A. Considering Emotion in COVID-19 Vaccine Communication: Addressing Vaccine Hesitancy and Fostering Vaccine Confidence. Health Commun. 2020, 35, 1718–1722. [Google Scholar] [CrossRef] [PubMed]
- Friedman, S.R.; Pouget, E.R.; Sandoval, M.; Jones, Y.; Nikolopoulos, G.K.; Mateu-Gelabert, P. Measuring altruistic and soli-daristic orientations toward others among people Who inject drugs. J. Addict Dis. 2015, 34, 248–254. [Google Scholar] [CrossRef] [Green Version]
- Des Jarlais, D.C.; Perlis, T.; Arasteh, K.; Hagan, H.; Milliken, J.; Braine, N.; Yancovitz, S.; Mildvan, D.; Perlman, D.C.; Maslow, C. “Informed altruism” and “partner restriction” in the reduction of HIV infection in injecting drug users entering detoxifica-tion treatment in New York City, 1990–2001. JAIDS J. Acquir. Immune Defic. Syndr. 2004, 35, 158–166. [Google Scholar] [CrossRef]
- Goldman, R.D.; Yan, T.D.; Seiler, M.; Cotanda, C.P.; Brown, J.C.; Klein, E.J.; Hoeffe, J.; Gelernter, R.; Hall, J.E.; Davis, A.L.; et al. Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey. Vaccine 2020, 38, 7668–7673. [Google Scholar] [CrossRef]
- Bell, S.; Clarke, R.; Mounier-Jack, S.; Walker, J.L.; Paterson, P. Parents’ and guardians’ views on the acceptability of a future COVID-19 vaccine: A multi-methods study in England. Vaccine 2020, 38, 7789–7798. [Google Scholar] [CrossRef]
- Rhodes, A.; Hoq, M.; Measey, M.-A.; Danchin, M. Intention to vaccinate against COVID-19 in Australia. Lancet Infect. Dis. 2020, 21, e110. [Google Scholar] [CrossRef]
- Wang, Y.; McKee, M.; Torbica, A.; Stuckler, D. Systematic Literature Review on the Spread of Health-related Misinformation on Social Media. Soc. Sci. Med. 2019, 240, 112552. [Google Scholar] [CrossRef]
- Himelein-Wachowiak, M.; Giorgi, S.; Devoto, A.; Rahman, M.; Ungar, L.; Schwartz, H.A.; Epstein, D.H.; Leggio, L.; Curtis, B. Bots and Misinformation Spread on Social Media: Implications for COVID-19. J. Med. Internet Res. 2021, 23, e26933. [Google Scholar] [CrossRef]
- Lockyer, B.; Islam, S.; Rahman, A.; Dickerson, J.; Pickett, K.; Sheldon, T.; Wright, J.; McEachan, R.; Sheard, L.; the Bradford Institute for Health Research COVID-19 Scientific Advisory Group. Understanding COVID-19 misinformation and vaccine hesitancy in context: Findings from a qualitative study involving citizens in Bradford, UK. Health Expect. 2021, 24, 1158–1167. [Google Scholar] [CrossRef]
- Roozenbeek, J.; Schneider, C.R.; Dryhurst, S.; Kerr, J.; Freeman, A.L.J.; Recchia, G.; van der Bles, A.M.; van der Linden, S. Susceptibility to misinformation about COVID-19 around the world. R. Soc. Open Sci. 2020, 7, 201199. [Google Scholar] [CrossRef]
- A McKnight, C.; Shumway, M.; Masson, C.L.; Pouget, E.R.; Jordan, A.E.; Jarlais, D.C.D.; Sorensen, J.L.; Perlman, D.C. Perceived discrimination among racial and ethnic minority drug users and the association with health care utilization. J. Ethn. Subst. Abus. 2017, 16, 404–419. [Google Scholar] [CrossRef]
- Jenkins, W.D.; Bolinski, R.; Bresett, J.; Van Ham, B.; Fletcher, S.; Walters, S.; Friedman, S.; Ezell, J.M.; Pho, M.; Schneider, J.; et al. COVID-19 During the Opioid Epidemic—Exacerbation of Stigma and Vulnerabilities. J. Rural. Health 2020, 37, 172–174. [Google Scholar] [CrossRef] [Green Version]
- Blevins, J.L.; Edgerton, E.; Jason, D.P.; Lee, J.J. Shouting into the Wind: Medical Science versus “B.S.” in the Twitter Maelstrom of Politics and Misinformation About Hydroxychloroquine. Soc. Media Soc. 2021, 7. [Google Scholar] [CrossRef]
- Earnshaw, V.A.; Katz, I.T. Educate, Amplify, and Focus to Address COVID-19 Misinformation. JAMA Health Forum 2020, 1, e200460. [Google Scholar] [CrossRef]
- Hamel, L.; Lopes, L.; Kirzinger, A.; Sparks, G.; Stokes, M.; Brodie, M. KFF COVID-19 Vaccine Monitor: Media and misinfor-mation. Kais. Fam. Found. 2021. Available online: https://www.kff.org/coronavirus-covid-19/poll-finding/kff-covid-19-vaccine-monitor-media-and-misinformation/ (accessed on 1 July 2022).
- Centers for Disease Control and Prevention. County-level COVID-19 vaccination coverage and social vulnerability—United States, December 14, 2020–March 1, 2021. Morb. Mortal. Wkly. Rep. 2021, 70, 431. [Google Scholar] [CrossRef]
- Berenbrok, L.A.; Tang, S.; Coley, K.C.; Boccuti, C.; Guo, J.; Essien, U.R.; Dickson, S.; Hernandez, I. Access to Potential COVID-19 Vaccine Administration Facilities: A Geographic Information Systems Analysis. 2021. Available online: chrome-extension://efaidnbmnnnibpcajpcglclefindmkaj/https://s8637.pcdn.co/wp-content/uploads/2021/02/Access-to-Potential-COVID-19-Vaccine-Administration-Facilities-2-2-2021.pdf (accessed on 17 October 2022).
- Brown, C.C.; Young, S.G.; Pro, G.C. COVID-19 vaccination rates vary by community vulnerability: A county-level analysis. Vaccine 2021, 39, 4245–4249. [Google Scholar] [CrossRef]
- Michaels, I.H.; Pirani, S.J.; Carrascal, A. Peer Reviewed: Disparities in Internet Access and COVID-19 Vaccination in New York City. Prev. Chronic Dis. 2021, 18, E83. [Google Scholar] [CrossRef] [PubMed]
- Lazarus, J.V.; Ratzan, S.C.; Palayew, A.; Gostin, L.O.; Larson, H.J.; Rabin, K.; Kimball, S.; El-Mohandes, A. A global survey of potential acceptance of a COVID-19 vaccine. Nat. Med. 2021, 27, 225–228. [Google Scholar] [CrossRef] [PubMed]
- Kreps, S.; Prasad, S.; Brownstein, J.S.; Hswen, Y.; Garibaldi, B.T.; Zhang, B.; Kriner, D.L. Factors Associated with US Adults’ Likelihood of Accepting COVID-19 Vaccination. JAMA Netw. Open 2020, 3, e2025594. [Google Scholar] [CrossRef] [PubMed]
- Wake, A.D. The willingness to receive COVID-19 vaccine and its associated factors:“vaccination refusal could prolong the war of this pandemic”—A systematic review. Risk Manag. Healthc. Policy 2021, 14, 2609. [Google Scholar] [CrossRef] [PubMed]
- Lei, Y. Hyper Focusing Local Geospatial Data to Improve COVID-19 Vaccine Equity and Distribution. J. Hered. 2021, 98, 453–458. [Google Scholar] [CrossRef]
- Wrigley-Field, E.; Kiang, M.V.; Riley, A.R.; Barbieri, M.; Chen, Y.-H.; Duchowny, K.A.; Matthay, E.C.; Van Riper, D.; Jegathesan, K.; Bibbins-Domingo, K.; et al. Geographically targeted COVID-19 vaccination is more equitable and averts more deaths than age-based thresholds alone. Sci. Adv. 2021, 7. [Google Scholar] [CrossRef]
- Miller, W.R.; Rollnick, S. Motivational Interviewing: Helping People Change; Guilford Press: New York, NY, USA, 2012. [Google Scholar]
- Miller, W.R.; Rose, G.S. Motivational Interviewing and Decisional Balance: Contrasting Responses to Client Ambivalence. Behav. Cogn. Psychother. 2013, 43, 129–141. [Google Scholar] [CrossRef]
- Freeman, R.; Gwadz, M.V.; Silverman, E.; Kutnick, A.; Leonard, N.R.; Ritchie, A.S.; Reed, J.; Martinez, B.Y. Critical race theory as a tool for understanding poor engagement along the HIV care continuum among African American/Black and Hispanic persons living with HIV in the United States: A qualitative exploration. Int. J. Equity Health 2017, 16, 54. [Google Scholar] [CrossRef] [Green Version]
- Ritchie, A.; Gwadz, M.V.; Perlman, D.; De Guzman, R.; Leonard, N.R.; Cleland, C. Eliminating Racial/Ethnic Disparities in AIDS Clinical Trials in the United States: A Qualitative Exploration of an Efficacious Social/Behavioral Intervention. J. AIDS Clin. Res. 2017, 8, 648. [Google Scholar] [CrossRef]
- City of New York. Mayor de Blasio Announces Nation’s First Overdose Prevention Center Services to Open in New York City. 2021. Available online: https://www1.nyc.gov/office-of-the-mayor/news/793-21/mayor-de-blasio-nation-s-first-overdose-prevention-center-services-open-new-york (accessed on 29 October 2022).
Overall Sample | Willingness to Receive COVID-19 Vaccine | |||||||||
---|---|---|---|---|---|---|---|---|---|---|
Characteristic | n 1,2 | Percent 3 | 95% CI | Yes, n = 38 | Yes, % | 95% CI | No, n = 62 | No, % | 95% CI | p-Value |
People who use illicit drugs (past 30 days) | 100 | 100% | 38 | 38% | 37–39% | 62 | 62% | 61–63% | ||
Borough of interview | ||||||||||
Bronx | 46 | 46% | 37–58% | 20 | 53% | 37–68% | 26 | 42% | 30–54% | 0.635 |
Brooklyn | 4 | 4% | 12–10% | 1 | 3% | 0–13% | 3 | 5% | 2–13% | |
Manhattan | 22 | 22% | 15–31% | 7 | 18% | 9–33% | 15 | 24% | 15–36% | |
Queens | 24 | 24% | 17–33% | 7 | 18% | 9–33% | 17 | 27% | 18–40% | |
Borough of residence | ||||||||||
Bronx | 30 | 30% | 22–40% | 15 | 39% | 26–55% | 15 | 24% | 15–36% | 0.514 |
Brooklyn | 16 | 16% | 10–24% | 6 | 16% | 7–30% | 10 | 16% | 9–27% | |
Manhattan | 24 | 24% | 17–33% | 8 | 21% | 11–36% | 16 | 26% | 17–38% | |
Queens | 19 | 19% | 13–28% | 6 | 16% | 7–30% | 13 | 21% | 13–32% | |
Gender | ||||||||||
Male | 80 | 80% | 71–87% | 32 | 84% | 70–93% | 48 | 77% | 66–86% | 0.268 |
Female | 19 | 19% | 13–28% | 5 | 13% | 6–27% | 14 | 23% | 14–34% | |
Age, mean in years (SD) | 45 (10) | n/a | n/a | 38 | 47 (9) | n/a | 62 | 43 (10) | n/a | 0.024 6 |
Age category, in years | ||||||||||
18–29 | 6 | 6% | 3–12% | 1 | 3% | 0–13% | 5 | 8% | 3–18% | 0.096 7 |
30–39 | 26 | 26% | 18–35% | 5 | 13% | 6–27% | 21 | 34% | 23–46% | |
40–49 | 24 | 24% | 17–33% | 10 | 26% | 15–42% | 14 | 23% | 14–34% | |
50–59 | 40 | 40% | 31–50% | 20 | 53% | 37–68% | 20 | 32% | 22–45% | |
60–69 | 4 | 4% | 2–10% | 2 | 5% | 1–17% | 2 | 3% | 1–11% | |
Race/Ethnicity | ||||||||||
non-Hispanic Black | 22 | 22% | 15–31% | 11 | 29% | 17–45% | 11 | 18% | 10–29% | 0.384 8 |
non-Hispanic White | 30 | 30% | 22–40% | 9 | 24% | 13–39% | 21 | 34% | 23–46% | |
Other | 4 | 4% | 2–10% | 2 | 5% | 1–17% | 2 | 3% | 1–11% | |
Hispanic | 44 | 44% | 35–54% | 16 | 42% | 28–58% | 28 | 45% | 33–57% | |
Puerto Rican | 30 | 68% | 20–47% | 12 | 75% | 50–90% | 18 | 64% | 46–79% | |
Other Hispanic ancestries | 14 | 32% | 53–80% | 4 | 25% | 10–49% | 10 | 36% | 21–54 | |
Education | ||||||||||
Up to 8th grade | 11 | 11% | 6–19% | 2 | 5% | 1–17% | 9 | 15% | 8–25% | 0.204 8 |
Some high school | 27 | 27% | 19–36% | 11 | 29% | 17–48% | 16 | 26% | 16–38% | |
High school diploma or GED | 39 | 39% | 30–49% | 14 | 37% | 23–53% | 25 | 3% | 29–53% | |
Associate’s degree or some college | 17 | 17% | 11–26% | 8 | 21% | 11–36% | 9 | 15% | 8–25% | |
Bachelor’s degree | 4 | 4% | 2–10% | 2 | 5% | 1–17% | 2 | 3% | 0–11% | |
Master’s, professional or doctoral degree | 1 | 1% | 0–5% | 1 | 3% | 0–13% | 0 | 0% | n/a | |
Services accessed (past 30 days) 4 | ||||||||||
MOUD | 41 | 41% | 32–51% | 24 | 63% | 40–70% | 17 | 27% | 18–40% | n/a |
Primary care | 26 | 26% | 18–35% | 11 | 29% | 17–48% | 15 | 24% | 15–36% | |
HIV care | 8 | 8% | 4–15% | 3 | 8% | 3–21% | 5 | 8% | 3–18% | |
SSP | 33 | 33% | 25–43% | 13 | 34% | 21–50% | 20 | 32% | 22–45% | |
Other | 12 | 12% | 7–20% | 7 | 18% | 9–33% | 5 | 8% | 3–18% | |
Injection drug use (past 30 days) | ||||||||||
Yes | 47 | 47% | 38–57% | 21 | 55% | 40–70% | 26 | 42% | 30–54% | 0.221 |
No | 52 | 52% | 42–62% | 17 | 45% | 30–60% | 35 | 56% | 44–68% | |
Consistent internet access | ||||||||||
Yes | 65 | 65% | 55–74% | 23 | 61% | 45–74% | 42 | 68% | 55–78% | 0.374 |
No | 34 | 34% | 25–44% | 14 | 37% | 23–53% | 20 | 32% | 22–45% | |
Had a job that required in-person contact 5 | ||||||||||
Yes | 31 | 31% | 23–41% | 9 | 24% | 13–39% | 22 | 35% | 25–48% | 0.268 |
No | 66 | 66% | 56–75% | 26 | 68% | 53–81% | 13 | 21% | 13–33% |
Willingness to Receive COVID-19 Vaccine | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
n = 100 1 | % 1 | 95% CI | Yes n (n = 38) | Yes, % 1 | 95% CI | No n (n = 62) | No, % 1 | 95% CI | p-Value 2 | |
Friend or family diagnosed with COVID-19 | ||||||||||
Yes | 41 | 41% | 32–51% | 22 | 58% | 42–72% | 37 | 60% | 47–71% | 0.860 |
No | 59 | 59% | 49–68% | 16 | 42% | 28–58% | 25 | 40% | 29–53% | |
Thought COVID-19 most likely originated in a lab | ||||||||||
Yes | 67 | 67% | 57–75% | 20 | 53% | 37–68% | 47 | 76% | 64–85% | 0.017 |
No | 33 | 33% | 25–43% | 18 | 47% | 32–63% | 15 | 24% | 15–36% | |
Attempted to make COVID-19 vaccine appointment | ||||||||||
Yes | 23 | 23% | 16–32% | 17 | 45% | 30–60% | 6 | 10% | 5–20% | <0.001 |
No | 77 | 77% | 68–84% | 21 | 55% | 40–70% | 56 | 90% | 80–95% | |
Confidence level in decision about willingness to be COVID-19 vaccinated | ||||||||||
Very confident 3 | 70 | 70% | 60–78% | 27 | 71% | 55–83% | 43 | 69% | 57–36% | 0.857 |
Not very confident | 30 | 30% | 22–40% | 11 | 29% | 17–45% | 19 | 31% | 21–43% | |
Having a COVID-19 vaccine paused (n = 79) | ||||||||||
Would affect decision to be COVID-19 vaccinated | 58 | 73% | 48–67% | 17 | 57% | 30–60% | 41 | 84% | 71–91% | <0.001 |
Would not affect decision to be COVID-19 vaccinated | 21 | 27% | 14–30% | 13 | 43% | 21–50% | 8 | 16% | 9–29% | |
Having a COVID-19 vaccine reauthorized (n = 87) | ||||||||||
Would affect decision to be COVID-19 vaccinated | 64 | 74% | 54–73% | 21 | 62% | 40–70% | 43 | 81% | 69–89% | 0.046 |
Would not affect decision to be COVID-19 vaccinated | 23 | 26% | 16–32% | 13 | 38% | 21–50% | 10 | 19% | 11–31% | |
Received other adult vaccinations | ||||||||||
Yes | 76 | 76% | 67–83% | 30 | 79% | 64–89% | 46 | 74% | 62–83% | 0.59 |
No | 24 | 24% | 17–33% | 8 | 21% | 11–36% | 16 | 26% | 17–38% | |
Had concerns about how fast the COVID-19 vaccine was made and released | ||||||||||
Agree 4 | 74 | 74% | 65–82% | 26 | 68% | 53–81% | 48 | 77% | 66–86% | 0.319 |
Disagree | 26 | 26% | 18–35% | 12 | 32% | 19–47% | 14 | 23% | 14–34% | |
Would feel more comfortable receiving the COVID-19 vaccine if other respected people received it first | ||||||||||
Agree | 65 | 65% | 55–74% | 29 | 78% | 63–89% | 36 | 58% | 46–70% | 0.039 |
Disagree | 34 | 34% | 28–41% | 8 | 22% | 11–37% | 26 | 42% | 30–54% |
Willingness to Receive COVID-19 Vaccine | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
n = 100 1 | % 1 | 95% CI | Yes n (n = 38) | Yes, % 1 | 95% CI | No n (n = 62) | No, % 1 | 95% CI | p-Value 2 | |
Vaccines are important for the health of my community | ||||||||||
Agree 3 | 83 | 83% | 74–89% | 36 | 95% | 83–99% | 47 | 76% | 63–85% | 0.015 |
Disagree | 15 | 15% | 9–23% | 4 | 11% | 4–24% | 11 | 18% | 10–29% | |
My getting vaccinated for COVID-19 is important for the health of others in my community | . | |||||||||
Agree | 82 | 82% | 73–88% | 36 | 95% | 83–99% | 46 | 74% | 62–83% | 0.014 |
Disagree | 18 | 18% | 12–27% | 2 | 5% | 1–17% | 16 | 26% | 17–38% | |
Vaccine safety data is often fabricated | ||||||||||
Agree | 67 | 67% | 57–75% | 18 | 47% | 32–63% | 49 | 79% | 67–87% | 0.001 |
Disagree | 33 | 33% | 25–43% | 20 | 53% | 37–68% | 13 | 21% | 13–33% | |
Immunizing children is harmful, and this fact is covered up | ||||||||||
Agree | 64 | 64% | 54–73% | 17 | 45% | 30–60% | 47 | 76% | 64–85% | 0.002 |
Disagree | 18 | 18% | 12–27% | 14 | 37% | 23–53% | 4 | 6% | 3–15% | |
People are deceived about vaccine efficacy | ||||||||||
Agree | 76 | 76% | 67–83% | 22 | 58% | 42–72% | 54 | 87% | 77–93% | 0.001 |
Disagree | 24 | 24% | 17–33% | 16 | 42% | 28–58% | 8 | 13% | 7–23% | |
Vaccine efficacy data is often fabricated | ||||||||||
Agree | 70 | 70% | 60–78% | 20 | 53% | 37–68% | 50 | 82% | 71–90% | 0.002 |
Disagree | 29 | 29% | 21–39% | 18 | 47% | 32–63% | 11 | 18% | 10–29% | |
People are deceived about vaccine safety | ||||||||||
Agree | 77 | 77% | 68–84% | 22 | 58% | 42–72% | 55 | 89% | 78–94% | 0.001 |
Disagree | 23 | 23% | 16–32% | 16 | 42% | 28–58% | 7 | 11% | 6–22% | |
The government is trying to cover up the link between vaccines and autism | ||||||||||
Agree | 74 | 74% | 64–82% | 22 | 59% | 42–72% | 52 | 84% | 73–91% | 0.007 |
Disagree | 25 | 25% | 18–34% | 15 | 41% | 26–55% | 10 | 16% | 9–27% | |
New vaccines carry more risks than older vaccines | ||||||||||
Agree | 75 | 75% | 66–82% | 26 | 68% | 53–81% | 49 | 80% | 67–87% | 0.179 |
Disagree | 24 | 24% | 17–33% | 12 | 32% | 19–47% | 12 | 20% | 11–31% | |
I am concerned about serious adverse effects of COVID-19 vaccine | ||||||||||
Agree | 83 | 83% | 74–89% | 28 | 74% | 58–85% | 55 | 89% | 78–94% | 0.052 |
Disagree | 17 | 17% | 11–26% | 10 | 26% | 15–42% | 7 | 11% | 18–40% | |
I am confident that the COVID-19 vaccine is safe for people of my race/ethnicity | ||||||||||
Agree | 80 | 80% | 71–87% | 36 | 95% | 83–99% | 44 | 71% | 59–81% | 0.004 |
Disagree | 20 | 20% | 13–29% | 2 | 5% | 1–17% | 18 | 29% | 19–41% | |
I am confident that people of my race/ethnicity will have equal access to the COVID-19 vaccine compared to other race/ethnicities | ||||||||||
Agree | 73 | 73% | 64–81% | 31 | 84% | 67–91% | 42 | 68% | 55–78% | 0.079 |
Disagree | 26 | 26% | 18–35% | 6 | 16% | 7–30% | 20 | 32% | 22–44% | |
I am confident that the COVID-19 vaccine is safe for people who use drugs | ||||||||||
Agree | 78 | 78% | 69–85% | 36 | 95% | 83–99% | 42 | 68% | 55–78% | 0.002 |
Disagree | 22 | 22% | 15–31% | 2 | 5% | 1–17% | 20 | 32% | 22–44% | |
I am confident that PWUD will have equal access to the COVID-19 vaccine compared to people who do not use drugs | ||||||||||
Agree | 42 | 42% | 33–52% | 14 | 37% | 23–53% | 28 | 45% | 33–57% | 0.413 |
Disagree | 58 | 58% | 48–67% | 24 | 63% | 47–77% | 34 | 55% | 43–67% |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Jordan, A.E.; Izar, R.; Nicolas, R.; Beharie, N.; Harocopos, A. Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs. Vaccines 2022, 10, 2044. https://doi.org/10.3390/vaccines10122044
Jordan AE, Izar R, Nicolas R, Beharie N, Harocopos A. Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs. Vaccines. 2022; 10(12):2044. https://doi.org/10.3390/vaccines10122044
Chicago/Turabian StyleJordan, Ashly E., Rwaida Izar, Renée Nicolas, Nisha Beharie, and Alex Harocopos. 2022. "Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs" Vaccines 10, no. 12: 2044. https://doi.org/10.3390/vaccines10122044
APA StyleJordan, A. E., Izar, R., Nicolas, R., Beharie, N., & Harocopos, A. (2022). Understanding Vaccine Perceptions and Willingness to Receive COVID-19 Vaccination: Opportunities to Strengthen Public Health Responses and COVID-19 Services for People Who Use Drugs. Vaccines, 10(12), 2044. https://doi.org/10.3390/vaccines10122044